Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-alpha plus ribavirin

J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):238-40. doi: 10.1097/01.qai.0000148535.97081.72.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use*
  • Cohort Studies
  • Eligibility Determination
  • Female
  • HIV Infections / complications*
  • Hepatitis C, Chronic / complications*
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon Type I / therapeutic use*
  • Male
  • Polyethylene Glycols / therapeutic use
  • Prospective Studies
  • Recombinant Proteins
  • Ribavirin / therapeutic use*

Substances

  • Antiviral Agents
  • Interferon Type I
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin